Lancet Gastroen Hepatol: Sofibouwe in conjunction with Reddy Pavee to treat HCV infection patients with chronic kidney disease

For patients infectedhepatitis C virus (HCV) with severe kidney impairment, an efficient, safe, and well-tolerated treatment is requiredRecently, researchers in the absence of dialysis type 1 or 3 HCVinfectionaccompanied by stage 4-5 chronic kidney disease patients, Sofibwe combined libavirin or Reddy pavew joint sofy safety and efficacythe study is phase 2b and is being conducted in the United States and New ZealandThe patient has type 1 or type 3 HCV infection, the creatinine removal rate is less than or equal to 30 ml/min, no dialysisIn queues 1 and 2, patients were treated with Sofibwe (200 mg in queue 1 and 400 mg in queue 2) plus ribavirin 200 mg, once a day, for 24 weeksIn queue 3, 18 patients received treatment of 90mg redpave and 400mg Sofibuvir once a day for 12 weeksThe main outcome of the treatment was the proportion of patients receiving a continuous virological response (SVR12) 12 weeks after the end of treatment32 patients were treated with Sofibwe United Libavirin and 18 patients were treated by Sofibwe United ReddypaweOf the 10 patients in Queue 1 (40%), 6 (60%) of the 10 patients in Queue 2 reached SVR12, and all 18 patients (100%) in Queue 3 reached SVR12Adverse events are mostly mild or moderately severeOverall, the most commonly reported adverse events were headache (21%), anemia (18%) and fatigue (16%)Eight patients had severe adverse events, none of which were treatedNo adverse heart events associated with treatment were found, nor were there clinical significant changes in echocardiogram parameters or renal function studies have concluded that Sofibwe's combination of Reddy Paver treatment can be effective in treating patients with HCV infection with out-of-dialysis disease sepsis 4-5